FDA Clearance Tracker · P110027
THERASCREEN KRAS RGQ PCR KIT
Last checked: Nov 20, 2026Latest source record: May 23, 2014 (this decision)Source: openFDAMethods & limitations
Decided
May 23, 2014
Approved
Time to decision
1,033 days
Received Jul 25, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P110027
- Device name
- THERASCREEN KRAS RGQ PCR KIT
- Applicant
- QIAGEN GmbH
- Applicant location
- Hilden
- Received
- Jul 25, 2011
- Decided
- May 23, 2014
- Decision
- Approved
- Supplements
- 17 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Somatic gene mutation detection system (OWD)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE THERASCREEN KRAS RGQ PCR KIT, WHICH IS TO BE USED AS A COMPANION DIAGNOSTIC FOR THE DRUG VECTIBIX (PANITUMUMAB). THIS DEVICE IS INDICATED FOR:THE THERASCREEN KRAS RGQ PCR KIT IS A REAL-TIME QUALITATIVE PCR ASSAY USED ON THE ROTOR-GENE Q MDX INSTRUMENT FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN THE HUMAN KRAS ONCOGENE, USING DNA EXTRACTED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE), COLORECTAL CANCER (CRC) TISSUE. THE THERASCREEN KRAS RGQ PCR KIT IS INTENDED TO AID IN THE IDENTIFICATION OF CRC PATIENTS FOR TREATMENT WITH ERBITUX (CETUXIMAB) AND VECTIBIX (PANITUMUMAB) BASED ON A KRAS NO MUTATION DETECTED TEST RESULT.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OWD. The earliest in FDA's data is P110020, decided Aug 17, 2011.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for QIAGEN GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262168 · Decided Sep 24, 2026 · 90 days after receipt
Device type: Gram-Negative Bacteria And Associated Resistance Markers (PEN) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.